Certara (NASDAQ:CERT) Stock Price Down 5.7% – Here’s What Happened

Certara, Inc. (NASDAQ:CERT)’s share price dropped 5.7% on Friday . The stock traded as low as $6.87 and last traded at $6.8660. 793,302 shares were traded during trading, a decline of 78% from the average session volume of 3,683,374 shares. The stock had previously closed at $7.28.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Robert W. Baird decreased their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Craig Hallum decreased their price target on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Tuesday, May 12th. Barclays dropped their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Stephens reduced their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, KeyCorp decreased their target price on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.85.

Certara Price Performance

The firm has a 50 day moving average price of $5.76 and a two-hundred day moving average price of $6.71. The company has a market cap of $1.08 billion, a P/E ratio of -69.19 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88.

Certara (NASDAQ:CERT) last issued its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.Certara’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, analysts predict that Certara, Inc. will post 0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Several hedge funds have recently made changes to their positions in CERT. Northwestern Mutual Wealth Management Co. raised its stake in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares during the period. Osaic Holdings Inc. boosted its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the last quarter. Finally, Chicago Partners Investment Group LLC purchased a new stake in Certara in the first quarter valued at approximately $78,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.